Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial
Nalinie Joharatnam‐Hogan(MRC Clinical Trials Unit at UCL), R. Steele(University of Dundee), Alistair Ring(National Health Service), Komel Khabra(MRC Clinical Trials Unit at UCL), Lindy Berkman, Stephen Falk(At Bristol), Kinnari Patel(Churchill Hospital), Ruth E. Langley(MRC Clinical Trials Unit at UCL), Mahesh Parmar(University College London), Richard Adams(Velindre Cancer Centre), Kamalnayan Gupta(Worcestershire Royal Hospital), Peter M. Rothwell(UK Dementia Research Institute), Sam Rowley(MRC Clinical Trials Unit at UCL), Arnold Goldman, Tim Underwood(Southampton General Hospital), John Burn(Newcastle University), Mairead MacKenzie(The Patients Association), Yvonne Carse, Verity Henson(At Bristol), Fay Cafferty(MRC Clinical Trials Unit at UCL), Anne Crossley(St James's University Hospital), C.S. Pramesh(Homi Bhabha National Institute), Richard H. Wilson(Arizona State University), Farhat V N Din(Western General Hospital), Timothy Iveson(University Hospital Southampton NHS Foundation Trust), Victoria Kunene(Walsall Manor Hospital), Sudeep Gupta(Homi Bhabha National Institute), Sue Campbell, Anne Thomas(Leicester Royal Infirmary), Janet Graham(Beatson West of Scotland Cancer Centre), Daniel Swinson(St James's University Hospital), Lisa Capaldi, Duncan C. Gilbert(Royal Sussex County Hospital), Richard Hubner(The Christie Hospital), Howard Kynaston(Cardiff University), John Bridgewater(University College London Hospitals NHS Foundation Trust), Janusz Jankowski(University College London), Sharmila Sothi(University Hospital Coventry), Nicola Warner(Stoke Mandeville Hospital), Gregory Leonard, Russell Petty, Durga Gadgil, David Cameron(Corewell Health)
Cited by 64
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k